Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Number One Question For Valeant: What Next?

This article was originally published in The Pink Sheet Daily

Executive Summary

Now that the hostile bid for Cephalon has fallen through, Valeant's CEO sees "no shortage of exciting opportunities" but says there's no hurry.

You may also be interested in...



Valeant’s Latest M&A Gambit Hits Snag With Ista’s Rejection Of $314 Million Buyout Offer

The industry’s third largest ophthalmology company turns down a $6.50-per-share offer, saying the bid grossly undervalues the potential of its pipeline.

Valeant Adds To Dermatology Business By Acquiring Sanofi's Dermik For $425 Million

Sanofi divests its U.S and Canadian dermatology business to focus on core areas; Valeant beefs up skin care franchise and adds manufacturing capacity.

Valeant Adds To Dermatology Business By Acquiring Sanofi's Dermik For $425 Million

Sanofi divests its U.S and Canadian dermatology business to focus on core areas; Valeant beefs up skin care franchise and adds manufacturing capacity.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072343

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel